149
in all cases of osteonecrosis of the jaw, provided that the systemic
condition of the patient permits the surgical approach.
http://dx.doi.org/10.1016/j.ijom.2017.02.513Palatal hyperpigmentation associated with imatinib mesylate
therapy: a report of 2 rare cases
A. Shi
∗
, Q.Q. Lee, J.B. Lai, C. Sim
Department of Oral and Maxillofacial Surgery, National Dental
Centre Singapore, Singapore
Background:
Imatinib mesylate (Glivec
®
, Gleevec
®
, STI-571) is
a tyrosine kinase inhibitor currently used as the first-line medi-
cation for a number of malignant and haematological conditions.
One major indication of its use is for chronic myeloid leukaemia to
increase survival rates of these patients
. 1 Anumber of minor side
effects are commonly reported including dermatological hypopig-
mentation. Comparatively, reports of mucosal hyperpigmentation
are rare
. 2Case report:
We report two rare cases of hyperpigmentation of
the palatal mucosa associated with imatinib mesylate therapy to
treat chronic myeloid leukaemia. A diffuse, bluish-grey lesion
located at the hard palate was observed in both patients. Inci-
sional biopsies were performed and histological features of benign
hyperpigmentation were described.
Discussion:
c-Kit signalling may have a role to play in hyper-
pigmentation of the oral mucosa. It is important for clinicians
to recognise hyperpigmentation of the palatal mucosa associated
with imatinib mesylate therapy and distinct them frommelanoma.
They need to consider it in their differential diagnoses of oral
melanosis.
Conclusion:
Clinicians should be cognisant that hyperpigmenta-
tion of the palatal mucosa is a rare side effect of imatinib mesylate
therapy.
Reference
Gambacorti-Passerini, C., Antolini, L., Mahon, F. X., Guilhot, F., Deininger,
M., Fava, C., et al. (2011). Multicenter independent assessment of out-
comes in chronic myeloid leukemia patients treated with imatinib.
J Natl
Cancer Inst
,
103
, 553–561.
McPherson, T., Sherman, V., & Turner, R. (2009). Imatinib-associated
hyperpigmentation, a side effect that should be recognized.
J Eur Acad
Dermatol Venereol
,
23
, 82–83.
http://dx.doi.org/10.1016/j.ijom.2017.02.514Adolescence noma with facial defect and trismus (case
report)
M. Sylvyana
∗
, S. Adiantoro, A. Arumsari
Department of Oral and Maxillofacial Surgery, RSUP Dr. Hasan
Sadikin, Bandung, Indonesia
Noma is described as gangrenous infection of the oral and max-
illofacial region. Patients with noma are mostly children with
malnutrition and immunocompromised. Since the development on
health care in Indonesia and the availability of antibiotics, noma
cases become very rare.
This paper report 2 cases of adolescence noma with orofacial
defect and trismus.
Case 1: A 30-year-old male was referred to the oral and max-
illofacial surgery clinic at Dr. Hasan Sadikin Hospital from ETT
Department. The chief complaint was large defect of right lip with
restricted mouth opening. The examination revealed tuberculosis
(TB) infection with pseudomembrane at larynx. A further check
on human immunodeficiency virus (HIV) infection correlatedwith
clinical symptoms.
Case 2: A 38-year-old female presented to the oncology depart-
ment with orofacial defect and trismus. Patient showed features of
malnutrition. The oncology department has had the diagnosis of
inflammatory pseudotumour upon the biopsy. Dental examination
showed the impacted teeth of 38 and massive periodontal infection
from 33 to 38.
Treatment to both cases proceeded with regional flap for defect
closure, muscular release for contracture area. The surgical treat-
ment followed with nutritional care and physiotherapy. The patient
with TB and suspected HIV, was referred to the internal medicine
department.
http://dx.doi.org/10.1016/j.ijom.2017.02.515Aetiology of oral health problems in Crohn’s disease
C.X.W. Tan
∗
, H.S. Brand, S. Iqbal, T. Forouzanfar
VU Medical Centre, Amsterdam, The Netherlands
Background:
Inflammatory bowel disease (IBD) not only affects
the intestinal tract but may also have oral manifestations. The
aetiology of these oral manifestations is not exactly known.
Objectives:
To investigate whether inflammation of the intestine
is an aetiological factor of the oral manifestations or that there is
another aetiological factor that causes both the intestinal and oral
manifestations.
Methods:
To exclude the inflamed intestine as an aetiological
factor, this study was conducted in association with the Stoma
Association Netherlands. A validated oral health questionnaire
was distributed by email to the members of this association. The
self-reported oral health from patients with a stoma due to IBD
was compared with age-and gender-matched patients with a stoma
due to colon cancer.
Findings:
The questionnaire was completed by 773 patients. 12%
had a stoma as a result of Crohn’s disease, 18% due to ulcerative
colitis and 43% due to colon cancer. Patients with Crohn’s disease
reported significantly more oral health problems than patients with
a stoma due to colon cancer or ulcerative colitis. Crohn patients
with a stoma especially suffered more frequently from aphthae
and discolorations of the oral mucosa. The increased incidence of
oral problems in Crohn’s patients was not related to differences in
tooth brushing frequency or interdental space cleaning.
Conclusion:
Patients with Crohn’s disease have an increased
risk for oral health problems, which remains after removal of
the affected part of the intestine, suggesting a general increased
susceptibility of Crohn’s disease patients for oral health problems.
http://dx.doi.org/10.1016/j.ijom.2017.02.516




